Actelion Stock

Equities

17-07-31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
17-07-18	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
17-07-18	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
17-06-09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
17-06-09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
17-06-09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
17-05-22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
17-05-18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
17-04-20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
17-04-18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
17-04-05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
17-03-31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
17-02-22	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

20-04-06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
17-10-31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
17-06-30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
17-06-16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
17-06-15	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

18-01-29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
18-01-29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
18-01-22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
17-10-31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
17-10-30	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ACTELION	-.--%	+0.99%	-	-	0
ARGENX SE	-0.61%	-4.57%	+5.07%	+91.15%	44.3B
WUXI APPTEC CO., LTD.	+0.92%	-4.81%	+55.76%	+12.07%	40B
INSMED INCORPORATED	-2.40%	-6.58%	+80.70%	+580.24%	30.95B
BIONTECH SE	-0.44%	-6.71%	-11.56%	-22.38%	25.58B
WUXI BIOLOGICS (CAYMAN) INC.	+2.54%	-5.07%	+57.32%	-37.07%	18.76B
GENMAB A/S	-2.62%	-5.78%	+4.47%	-32.53%	16.89B
AKESO, INC.	+5.20%	+5.30%	+46.09%	+144.70%	12.02B
SUMMIT THERAPEUTICS INC.	+1.14%	-4.37%	-22.71%	+881.17%	11.58B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.43%	+1.36%	+59.06%	-	11.03B
Average	+0.90%	-4.04%	+30.46%	+202.17%	23.46B
Weighted average by Cap.	+0.35%	-4.13%	+31.97%	+162.97%